A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

NCT00537511 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated for administrative reasons.

Conditions

Carcinoma, Small Cell

Interventions

DRUG: Pomalidomide
DRUG: Cisplatin
DRUG: Etoposide

Sponsor

Celgene